SOUTH SAN FRANCISCO, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that it is scheduled to report third quarter results on October 31, 2019 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the companys outlook for the future.
The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics website at http://www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078 (international) and typing in the passcode 9440838.
An archived replay of the webcast will be available via Cytokinetics website until November 7, 2019. The replay will also be available via telephone by dialing (855) 859-2056 (United States and Canada) or (404) 537-3406 (international) and typing in the passcode 9440838 from October 31, 2019 at 7:30 PM Eastern Time until November 7, 2019.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is collaborating with Amgen Inc. (Amgen) to develop omecamtiv mecarbil, a novel cardiac muscle activator. Omecamtiv mecarbil is the subject of an international clinical trials program in patients with heart failure including GALACTIC-HF and METEORIC-HF. Amgen holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and certain other countries. Cytokinetics is collaborating with Astellas Pharma Inc. (Astellas) to develop reldesemtiv, a fast skeletal muscle troponin activator (FSTA) for diseases of neuromuscular dysfunction, including SMA and ALS. Astellas holds an exclusive worldwide license to develop and commercialize reldesemtiv. Licenses held by Amgen and Astellas are subject to specified co-development and co-commercialization rights of Cytokinetics. Cytokinetics is also developing CK-274, a novel cardiac myosin inhibitor that company scientists discovered independent of its collaborations, for the potential treatment of hypertrophic cardiomyopathies. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.
For additional information aboutCytokinetics, visitwww.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").Cytokineticsdisclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act'sSafe Harborfor forward-looking statements. Examples of such statements include, but are not limited to, statements relating toCytokinetics'and its partners' research and development activities of Cytokinetics product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related toCytokinetics'business outlined inCytokinetics'filings with theSecurities and Exchange Commission. Forward-looking statements are not guarantees of future performance, andCytokinetics'actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements thatCytokineticsmakes in this press release speak only as of the date of this press release.Cytokineticsassumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Story continues
Contact:CytokineticsDiane WeiserVice President, Corporate Communications, Investor Relations(650) 624-3060
Excerpt from:
Cytokinetics to Announce Third Quarter Results on October 31, 2019 - Yahoo Finance
- Cardiomyopathy what it is and types British Heart Foundation - April 12th, 2018 [April 12th, 2018]
- Cardiomyopathy what it is and types British Heart ... - May 28th, 2018 [May 28th, 2018]
- Cardiomyopathy - what it is and types - British Heart ... - June 6th, 2018 [June 6th, 2018]
- Cardiomyopathy Symptoms, Types, Treatment & Prognosis - November 5th, 2018 [November 5th, 2018]
- Mark Drazner, M.D.: Internal Medicine | Cardiomyopathies ... - December 20th, 2018 [December 20th, 2018]
- Overview of Cardiomyopathies - Cardiovascular Disorders ... - December 27th, 2018 [December 27th, 2018]
- Cardiomyopathy | Cleveland Clinic - April 24th, 2019 [April 24th, 2019]
- Cardiomyopathy | pathology | Britannica.com - April 29th, 2019 [April 29th, 2019]
- Cardiomyopathy | Children's Hospital of Philadelphia - April 29th, 2019 [April 29th, 2019]
- Cardiac Surgery Instruments Market Prospects and Growth Assessment - TodayTimes - September 22nd, 2019 [September 22nd, 2019]
- Cardiovascular Genomic Diagnostics Market to Record an Exponential CAGR by 2025 - Rapid News Network - September 22nd, 2019 [September 22nd, 2019]
- Cardiovascular Genomic Diagnostics Market Estimated to Expand at a Robust CAGR over 2018 2028 - Space Market Research - October 9th, 2019 [October 9th, 2019]
- Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting - Yahoo Finance - October 9th, 2019 [October 9th, 2019]
- Cardiac Surgery Instruments Market to be Fueled by Increasing Threat of Cardiovascular Diseases - Online News Guru - October 21st, 2019 [October 21st, 2019]
- Cell Culture Protein Surface Coating Market Current Outlook Of Industry & Forecast 2017 2025 - Health News Office - October 24th, 2019 [October 24th, 2019]
- Lonza and DiNAQOR AG Announce Strategic Collaboration to Advance Gene Therapy Programs for Patients with Monogenic Cardiomyopathies - PRNewswire - November 29th, 2019 [November 29th, 2019]
- Lonza and DiNAQOR announce strategic collaboration to advance gene therapy programs for patients with monogenic cardiomyopathies - Pharmaceutical... - November 29th, 2019 [November 29th, 2019]
- Cytokinetics Announces New Results Presented at the International Symposium on ALS/MNDSubgroup Analyses of FORTITUDE-ALS on Effects of Reldesemtiv... - December 8th, 2019 [December 8th, 2019]
- Cell Culture Protein Surface Coating Market Competitive Environment and Higher Growth Rate with Forecast to 2025 - Filmi Baba - January 4th, 2020 [January 4th, 2020]
- New PET tracer provides insight on cardiac failure risk after heart attack - DOTmed HealthCare Business News - January 12th, 2020 [January 12th, 2020]
- PET tracer can help fight heart attacks earlier in the process - Health Imaging - January 12th, 2020 [January 12th, 2020]
- Atrial fibrillation in athletes - CMAJ - January 13th, 2020 [January 13th, 2020]
- Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure -... - February 9th, 2020 [February 9th, 2020]
- Cytokinetics to Announce Fourth Quarter Results on March 3, 2020 - Yahoo Finance - February 25th, 2020 [February 25th, 2020]
- Stealth BioTherapeutics to Present at 40th Annual Cowen Health Care Conference - PRNewswire - February 27th, 2020 [February 27th, 2020]
- Cell Culture Protein Surface Coating Market Analysis On Trends & Need 2025 - 3rd Watch News - March 18th, 2020 [March 18th, 2020]
- Heart patients dont need to panic: Doc - The Tribune India - March 18th, 2020 [March 18th, 2020]
- Stealth BioTherapeutics to Report Full Year 2019 Financial Results on Wednesday, April 1, 2020 - Yahoo Finance - April 1st, 2020 [April 1st, 2020]
- Stealth BioTherapeutics Reports Fiscal Year 2019 Financial Results And Recent Business Highlights - BioSpace - April 1st, 2020 [April 1st, 2020]
- Stealth BioTherapeutics to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020 - Tewksbury town crier - May 5th, 2020 [May 5th, 2020]
- BioMarin broadens its gene therapy horizons with a new R&D alliance in rare cardio cases - Endpoints News - May 5th, 2020 [May 5th, 2020]
- Tenaya Therapeutics to Present Preclinical Data at 2020 Annual Meeting of the American Society of Gene & Cell Therapy - thepress.net - May 12th, 2020 [May 12th, 2020]
- Stealth BioTherapeutics to Present at Upcoming Investor Conferences in September - Yahoo Finance - September 12th, 2020 [September 12th, 2020]
- What we know about what it's like to recover from Covid-19 and its long-term effects - Local News 8 - LocalNews8.com - October 7th, 2020 [October 7th, 2020]
- Should You Buy Myokardia Inc (MYOK) Stock After it Is Up 64.52% in a Week? - InvestorsObserver - October 7th, 2020 [October 7th, 2020]
- Heart Failure from ATTRwt Amyloid Cardiomyopathy is Associated with Poor Prognosis - DocWire News - October 7th, 2020 [October 7th, 2020]
- Relaxera and CBL Patras Announce Exclusive Agreement on Manufacturing and Sales of Synthetic Human R - PharmiWeb.com - December 16th, 2020 [December 16th, 2020]
- Counties combine push for more vaccines - The Record Newspapers - TheRecordLive.com - January 26th, 2021 [January 26th, 2021]
- Vet Speak: Cats are very good at hiding the signs of heart disease - RossShire Journal - January 26th, 2021 [January 26th, 2021]
- Stealth BioTherapeutics Reports First Quarter 2021 Financial Results And Recent Business Highlights - Yahoo Finance - May 25th, 2021 [May 25th, 2021]
- Suspicion of Frasier's syndrome in the nephrology unit | IMCRJ - Dove Medical Press - August 14th, 2021 [August 14th, 2021]
- Delta has set back herd immunity estimates. Heres how that affects the course of the pandemic - The Dallas Morning News - August 14th, 2021 [August 14th, 2021]
- Hypertrophic Cardiomyopathy Market to be Driven by the Emergence of Novel Pharmacotherapies & Gene-directed Approaches at a 22.24% CAGR During the... - August 14th, 2021 [August 14th, 2021]
- Stealth BioTherapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights - PRNewswire - November 18th, 2021 [November 18th, 2021]
- Cytokinetics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference - GuruFocus.com - November 18th, 2021 [November 18th, 2021]
- What is cardiac transplantation? An overview - Emergency Live International - October 6th, 2022 [October 6th, 2022]
- Fixing Heart Failure Workforce Issues: Baby Steps Start This Year - Medpage Today - January 10th, 2023 [January 10th, 2023]
- Inherited Cardiac Disease Genetic Diagnoses Linked to Ancestry ... - GenomeWeb - January 10th, 2023 [January 10th, 2023]
- VIDEO: Using genetics in cardiology to enable earlier interventions - Cardiovascular Business - January 10th, 2023 [January 10th, 2023]
- Ahmad Masri, MD, MS: 2024 Update on Development and Future of Cardiac Myosin Inhibitor Class - MD Magazine - February 20th, 2024 [February 20th, 2024]